Apontis Pharma AG
XETRA:APPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Apontis Pharma AG
XETRA:APPH
|
DE |
|
Net Insight AB
STO:NETI B
|
SE |
|
S
|
St Galler Kantonalbank AG
SIX:SGKN
|
CH |
|
A
|
Antong Holdings Co Ltd
SSE:600179
|
CN |
|
Tutor Perini Corp
NYSE:TPC
|
US |
|
Marker Therapeutics Inc
NASDAQ:MRKR
|
US |
|
National Medical Care Company JSC
SAU:4005
|
SA |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is APPH's stock price target?
Not Available
APPH doesn't have any price targets made by Wall Street professionals.
What is Apontis Pharma AG's Revenue forecast?
Projected CAGR
20%
For the last 4 years the compound annual growth rate for Apontis Pharma AG's revenue is 5%. The projected CAGR for the next 4 years is 20%.
What is Apontis Pharma AG's Operating Income forecast?
Projected CAGR
98%
The compound annual growth rate of Apontis Pharma AG's operating income for the next 4 years is 98%.
What is Apontis Pharma AG's Net Income forecast?
Projected CAGR
149%
The compound annual growth rate of Apontis Pharma AG's net income for the next 3 years is 149%.
